Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Tukysa
Tucatinib is a kinase inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens. It is a small molecule tyrosine kinase inhibitor that selectively targets HER2, a protein that can be overexpressed in certain types of cancer, including breast cancer. By inhibiting HER2, tucatinib helps slow down or stop the growth of cancer cells.
Tucatinib is used to treat advanced HER2-positive breast cancer, including cases with brain metastases, after prior anti-HER2 therapies.
Hepatotoxicity, including drug-induced liver injury. Monitor liver function tests. Severe diarrhea and colitis have also been reported.
Outcome:
Increased tucatinib exposure
Mechanism:
CYP3A4-mediated metabolism inhibition
Outcome:
Increased tucatinib exposure
Mechanism:
CYP3A4-mediated metabolism inhibition
Outcome:
Theoretical potential for hypertensive crisis (unlikely)
Mechanism:
MAO inhibition (weak)
Most likely new formulation: Combination therapy with other targeted agents (Year: 2025, 70% confidence)
Based on clinical trial data and post-marketing surveillance, tucatinib is expected to maintain its current regulatory status with ongoing monitoring for long-term safety and efficacy.
Kinase Inhibitor, Antineoplastic
Quinazoline derivative